Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | SCN1A | P35498 | 1/20 | 0.49 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.49 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | XBP1 | P17861 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | PRKCA | P17252 | 1/20 | 0.44 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17586310 | 0.90 | — | — | |
| SCHEMBL15831171 | 0.89 | GLA (0.47) | GLAALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL12558822 | 0.87 | GLA (0.46) | GLAALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL163027 | 0.86 | NPSR1 (0.53) | GLAALDH1A1MEN1KMT2ANPSR1 | |
| SCHEMBL13495293 | 0.84 | GLA (0.43) | GLAALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL29596750 | 0.84 | GLA (0.43) | GLAALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL1031984 | 0.84 | GLA (0.43) | GLAALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL1035514 | 0.84 | GLA (0.43) | GLAALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL15149194 | 0.84 | GLA (0.43) | GLAALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL29181615 | 0.84 | GLA (0.47) | GLAALDH1A1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 342 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317708-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-09-26 | — | — | US | claimed |
| EP-4192812-B1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-09-04 | — | — | EP | claimed |
| EP-4192813-B1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-08-14 | — | — | EP | claimed |
| CN-117800842-A | Synthesis method of adamantane methacrylate resin monomer containing carboxyl | 西安瑞联新材料股份有限公司 | 2024-04-02 | — | — | CN | claimed |
| CN-116806217-A | Substituted cyclic modulators of protein phosphatase 2A (PP 2A) and methods of use thereof | 拉帕塔疗法公司 | 2023-09-26 | — | — | CN | claimed |
| CN-105294428-B | 2-adamantanecarboxylic acid and 1-adamantane methanol separation and purification method | 浙江师范大学 | 2017-05-10 | — | — | CN | claimed |
| CN-103613603-B | Trithio is for adamantane derivative, its preparation method and application | SUZHOU QINGSHAN BIOTECHNOLOGY CO., LTD. (CN) | 2016-05-25 | — | — | CN | claimed |
| CN-105294428-A | 2-adamantanecarboxylic acid and 1-adamantane methanol separation and purification method | UNIV ZHEJIANG NORMAL | 2016-02-03 | — | — | CN | claimed |
| EP-2272825-B1 | Protected amino hydroxy adamantane carboxylic acid and process for its preparation | ASTRAZENECA AB (SE) | 2015-11-04 | — | — | EP | claimed |
| WO-2014057495-A1 | A PROCESS FOR INDUSTRIAL PREPARATION OF [(S)-N-TERT BUTOXYCARBONYL-3-HYDROXY]ADAMANTYLGLYCINE | LEE PHARMA LIMITED (IN) | 2014-04-17 | — | — | WO | claimed |
| EP-2104665-A2 | IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS FOR DIABETES | F. Hoffmann-Roche AG (CH) | 2009-09-30 | — | — | EP | claimed |
| WO-2008046758-A2 | IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS FOR DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-24 | — | — | WO | claimed |
| EP-1559710-A2 | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV, process for their preparation and their use | Bristol-Myers Squibb Company (US) | 2005-08-03 | — | — | EP | claimed |
| US-20040242465-A1 | Nucleotide analogs | BISCHOFBERGER NORBERT W (US) | 2004-12-02 | — | — | US | claimed |
| US-20010041794-A1 | Nucleotide analogs | GILEAD SCIENCES, INC. | 2001-11-15 | — | — | US | claimed |
| US-6225460-B1 | PHOSPHOAMIDATE OR ESTER BOND THAT IS HYDROLYZED IN VIVO TO YIELD A CORRESPONDING PHOSPHONATE NUCLEOTIDE ANALOG. | GILEAD SCIENCES, INC. | 2001-05-01 | — | — | US | claimed |
| US-5656745-A | AMIDATE LINKAGE; ANTITUMOR, ANTICARCINOGENIC AGENTS | GILEAD SCIENCES, INC. (US) | 1997-08-12 | — | — | US | claimed |
| EP-0719273-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1996-07-03 | — | — | EP | claimed |
| US-5491167-A | INHIBITORS OF CHOLESTEROL BIOSYNTHESIS | SANKYO COMPANY, LIMITED (JP) | 1996-02-13 | — | — | US | claimed |
| WO-1995007920-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1995-03-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242465-A1 | Nucleotide analogs | PNP, NUDT1, TYMP | GLA 1418/4885ALDH1A1 4101/4885MAPT 4469/4885 |
| US-20010041794-A1 | Nucleotide analogs | PNP, NUDT1, TYMP | GLA 1418/4885ALDH1A1 4101/4885MAPT 4469/4885 |
| US-20240317708-A1 | INHIBITORS OF TRANSGLUTAMINASES | TGM2, TGM3, TGM1 | GLA 17/4885ALDH1A1 1825/4885MAPT 989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.